Human Osteoclast Precursor Cells
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The preservation and restoration of bone tissue involve osteoblasts, responsible for bone formation, and osteoclasts, accountable for bone resorption. Osteoclasts, multinucleated cells that absorb bone, originate from pluripotential hematopoietic stem cells and share precursor cells with the mononuclear phagocyte system. The ligand RANKL, produced by osteoblasts, along with M-CSF, facilitates the development of active osteoclasts when introduced to osteoclast precursor cultures. Retinoic Acid enhances the proliferation of human osteoclast progenitors and hinders RANKL-induced osteoclast differentiation by suppressing the RANK receptor.
Why choose Human Osteoclast Precursor Cells from AcceGen?
AcceGen’s Human Osteoclast Precursor Cells are favored for their high yield of up to 50% conversion to osteoclasts during differentiation. These cryopreserved cells assure over 1 million viable cells per ampoule, demonstrating osteoclast activity and TRAP staining post-differentiation. Additionally, they are free from HIV-1, hepatitis B, and hepatitis C, ensuring every cell lot safety.
Species | Human |
Cat.No | ABC-H0014X |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Osteoclast |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Disease | Normal |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Blood Products |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
Human Osteoclast Precursor Cells find versatile applications, notably in high-throughput studies targeting osteoporosis, bone resorption, and related diseases. They offer insights into environmental impacts on osteoclast formation and pathogenic derivation, while also enabling exploration of regulators like chemokines and M-CSF influencing osteoclast precursor cell recruitment to bone. Enhanced comprehension of OCPs’ nature, heterogeneity, and recruitment pathways holds promise for targeted therapies addressing osteoclast-specific concerns.